# Talmadge E King Jr

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/12170428/talmadge-e-king-jr-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128 76 31,104 127 h-index g-index citations papers 10.8 128 36,589 6.7 L-index avg, IF ext. citations ext. papers

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 127 | An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 788-824   | 10.2 | 4665      |
| 126 | An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 733-48 | 10.2 | 2176      |
| 125 | A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2083-92  | 59.2 | 2111      |
| 124 | Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. <i>Lancet, The,</i> <b>2011</b> , 377, 1760-9   | 40   | 1286      |
| 123 | Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 136-51   | 8    | 1257      |
| 122 | Idiopathic pulmonary fibrosis. <i>Lancet, The</i> , <b>2011</b> , 378, 1949-61  | 40   | 1196      |
| 121 | Clinical course and prediction of survival in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 431-40  | 10.2 | 998       |
| 120 | Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1968-77  | 59.2 | 992       |
| 119 | Acute exacerbations of idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 636-43   | 10.2 | 823       |
| 118 | A multidimensional index and staging system for idiopathic pulmonary fibrosis. <i>Annals of Internal Medicine</i> , <b>2012</b> , 156, 684-91   | 8    | 642       |
| 117 | Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2003</b> , 168, 538-42  | 10.2 | 556       |
| 116 | A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 125-33  | 59.2 | 545       |
| 115 | Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 904-10  | 10.2 | 450       |
| 114 | Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 177, 1338-47   | 10.2 | 425       |
| 113 | The clinical course of patients with idiopathic pulmonary fibrosis. <i>Annals of Internal Medicine</i> , <b>2005</b> , 142, 963-7   | 8    | 423       |
| 112 | BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 177, 75-81   | 10.2 | 407       |
| 111 | An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. <i>The American Review of Respiratory Disease</i> , <b>1989</b> , 140, 1693-703   |      | 390       |

### (2009-2009)

| 110 | Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 222-8                           | 40   | 376 |
|-----|--|------|-----|
| 109 | High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 172, 488-93                                     | 10.2 | 373 |
| 108 | Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2093-101  | 59.2 | 343 |
| 107 | BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 92-9  | 10.2 | 333 |
| 106 | Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 1390-4                 | 10.2 | 313 |
| 105 | Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 1382-9 | 10.2 | 306 |
| 104 | Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 184, 459-66                                     | 10.2 | 294 |
| 103 | Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 691-7                   | 10.2 | 293 |
| 102 | Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2011</b> , 183, 1231-7                | 10.2 | 291 |
| 101 | Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 186, 314-24  | 10.2 | 287 |
| 100 | Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. <i>American Journal of Medicine</i> , <b>1990</b> , 88, 396-404  | 2.4  | 282 |
| 99  | Classification and natural history of the idiopathic interstitial pneumonias. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 285-92  |      | 276 |
| 98  | Idiopathic interstitial pneumonias: CT features. <i>Radiology</i> , <b>2005</b> , 236, 10-21   | 20.5 | 259 |
| 97  | Predicting survival across chronic interstitial lung disease: the ILD-GAP model. <i>Chest</i> , <b>2014</b> , 145, 723-72  | 85.3 | 253 |
| 96  | A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. <i>The American Review of Respiratory Disease</i> , <b>1986</b> , 133, 97-103           |      | 251 |
| 95  | Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. <i>Chest</i> , <b>2003</b> , 124, 1215-23   | 5.3  | 247 |
| 94  | Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 243-53   | 13.6 | 244 |
| 93  | Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. <i>Chest</i> , <b>2009</b> , 136, 1397-1405  | 5.3  | 237 |

| 92 | Clinical advances in the diagnosis and therapy of the interstitial lung diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 172, 268-79  | 10.2 | 215 |
|----|--|------|-----|
| 91 | Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. <i>PLoS ONE</i> , <b>2007</b> , 2, e482   | 3.7  | 205 |
| 90 | Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 175, 1054-60                                      | 10.2 | 190 |
| 89 | Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2013</b> , 144, 234-240  | 5.3  | 186 |
| 88 | Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2005</b> , 127, 171-7   | 5.3  | 181 |
| 87 | The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 662-8   | 2.4  | 174 |
| 86 | Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. <i>The American Review of Respiratory Disease</i> , <b>1989</b> , 139, 1479-86            |      | 168 |
| 85 | The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. <i>Respiratory Medicine</i> , <b>2010</b> , 104, 296-304  | 4.6  | 167 |
| 84 | Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2008</b> , 133, 226-32  | 5.3  | 166 |
| 83 | Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 185, 1044-8                                 | 10.2 | 165 |
| 82 | Prevalence and prognosis of unclassifiable interstitial lung disease. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 750-7  | 13.6 | 164 |
| 81 | Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 214-22   | 10.2 | 159 |
| 80 | Does chronic microaspiration cause idiopathic pulmonary fibrosis?. <i>American Journal of Medicine</i> , <b>2010</b> , 123, 304-11   | 2.4  | 156 |
| 79 | Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2009</b> , 135, 1557-1563  | 5.3  | 152 |
| 78 | Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 166, 236-46 | 10.2 | 140 |
| 77 | Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2010</b> , 299, L3-7                                       | 5.8  | 139 |
| 76 | 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 1421-9   | 13.6 | 128 |
| 75 | Current perspectives on the treatment of idiopathic pulmonary fibrosis. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 330-8   |      | 124 |

# (2007-2012)

| 74 | Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. <i>Thorax</i> , <b>2012</b> , 67, 407-11   | 7.3                 | 117 |
|----|---|---------------------|-----|
| 73 | Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. <i>Chest</i> , <b>2013</b> , 144, 586-592  | 5.3                 | 117 |
| 72 | Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. <i>Chest</i> , <b>2004</b> , 125, 2169-74  | 5.3                 | 112 |
| 71 | Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. <i>Journal of Computer Assisted Tomography</i> , <b>2002</b> , 26, 13-20  | 2.2                 | 112 |
| 7° | Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. <i>Thorax</i> , <b>2016</b> , 71, 429-35 | 7-3                 | 112 |
| 69 | Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. <i>The American Review of Respiratory Disease</i> , <b>1991</b> , 144, 892-900  |                     | 104 |
| 68 | Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 166, 765-7  | , <sub>1</sub> 10.2 | 101 |
| 67 | Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. <i>The American Review of Respiratory Disease</i> , <b>1991</b> , 144, 160-6  |                     | 99  |
| 66 | The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. <i>Thorax</i> , <b>2010</b> , 65, 173-7  | 7.3                 | 97  |
| 65 | Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. <i>Respirology</i> , <b>2014</b> , 19, 493-500   | 3.6                 | 95  |
| 64 | CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. <i>Lancet Respiratory Medicine,the</i> , <b>2015</b> , 3, 483-96                            | 35.1                | 95  |
| 63 | All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 825                     | 5-31 <sup>2</sup>   | 92  |
| 62 | Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. <i>Radiology</i> , <b>2014</b> , 270, 583-8   | 20.5                | 91  |
| 61 | Pathogenesis of pulmonary fibrosis in interstitial lung disease. Alveolar macrophage PDGF(B) gene activation and up-regulation by interferon gamma. <i>The American Review of Respiratory Disease</i> , <b>1991</b> , 143, 167-73                     |                     | 90  |
| 60 | Acute interstitial pneumonitis. Case series and review of the literature. <i>Medicine (United States)</i> , <b>2000</b> , 79, 369-78  | 1.8                 | 89  |
| 59 | Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. <i>The American Review of Respiratory Disease</i> , <b>1988</b> , 138, 74-80   |                     | 87  |
| 58 | Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 490-3  | 2.4                 | 86  |
| 57 | Respiratory bronchiolitis-interstitial lung disease: long-term outcome. <i>Chest</i> , <b>2007</b> , 131, 664-671   | 5.3                 | 85  |

| 56 | The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. <i>Thorax</i> , <b>2017</b> , 72, 424-429   | 7.3           | 81 |
|----|--|---------------|----|
| 55 | Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. <i>Respirology</i> , <b>2014</b> , 19, 740-7   | 3.6           | 79 |
| 54 | Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. <i>The American Review of Respiratory Disease</i> , <b>1988</b> , 137, 585-91  |               | 78 |
| 53 | Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. <i>BMJ Open Respiratory Research</i> , <b>2016</b> , 3, e000105   | 5.6           | 77 |
| 52 | RESPIRATORY BRONCHIOLITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. <i>Clinics in Chest Medicine</i> , <b>1993</b> , 14, 693-698   | 5.3           | 76 |
| 51 | Demystifying idiopathic interstitial pneumonia. <i>Archives of Internal Medicine</i> , <b>2003</b> , 163, 17-29  |               | 70 |
| 50 | American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. <i>Radiographics</i> , <b>2015</b> , 35, 1849-71  | 5.4           | 69 |
| 49 | Cryptogenic Organizing Pneumonitis. <i>Chest</i> , <b>1992</b> , 102, 8-13   | 5.3           | 69 |
| 48 | Idiopathic pulmonary fibrosis: CT and risk of death. <i>Radiology</i> , <b>2014</b> , 273, 570-9   | 20.5          | 66 |
| 47 | Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. <i>Thorax</i> , <b>2007</b> , 62, 546-53   | 7-3           | 65 |
| 46 | Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2013</b> , 107, 249-55   | 4.6           | 64 |
| 45 | Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. <i>Lancet Respiratory Medicine,the</i> , <b>2015</b> , 3, 388-96 | 35.1          | 57 |
| 44 | Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 914-2                                  | 2 <b>2</b> .6 | 55 |
| 43 | Collagen cross-linking in adult patients with acute and chronic fibrotic lung disease. Molecular markers for fibrotic collagen. <i>The American Review of Respiratory Disease</i> , <b>1990</b> , 141, 307-13  |               | 53 |
| 42 | A diagnostic model for chronic hypersensitivity pneumonitis. <i>Thorax</i> , <b>2016</b> , 71, 951-4   | 7.3           | 53 |
| 41 | The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. <i>The American Review of Respiratory Disease</i> , <b>1991</b> , 144, 1102-6  |               | 52 |
| 40 | Idiopathic pulmonary fibrosis. Quantitative assessment of lung pathology. Comparison of a semiquantitative and a morphometric histopathologic scoring system. <i>The American Review of Respiratory Disease</i> , <b>1992</b> , 146, 1042-7                  |               | 50 |
| 39 | Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. <i>Thorax</i> , <b>2007</b> , 62, 1008-12   | 7.3           | 45 |

# (2005-2010)

| 38       | Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. <i>Lung</i> , <b>2010</b> , 188, 143-9   | 2.9         | 42 |
|----------|---|-------------|----|
| 37       | Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. <i>Chest</i> , <b>2017</b> , 152, 999-1007  | 5.3         | 40 |
| 36       | Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. <i>The American Review of Respiratory Disease</i> , <b>1992</b> , 146, 701-6   |             | 39 |
| 35       | Workshop on idiopathic pulmonary fibrosis in older adults. <i>Chest</i> , <b>2010</b> , 138, 693-703  | 5.3         | 37 |
| 34       | Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. <i>Respiratory Medicine</i> , <b>2007</b> , 101, 2011-6   | 4.6         | 37 |
| 33       | A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. <i>European Respiratory Journal</i> , <b>2015</b> , 46, 243-9  | 13.6        | 35 |
| 32       | The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. <i>Respiratory Medicine</i> , <b>2017</b> , 127, 51-56   | 4.6         | 33 |
| 31       | Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1326-31   | 4.6         | 33 |
| 30       | Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. <i>American Journal of Medicine</i> , <b>2001</b> , 110, 326-8  | 2.4         | 30 |
| 29       | COPD: a dust-induced disease?. <i>Chest</i> , <b>2005</b> , 128, 3055-64  | 5.3         | 28 |
| 28       | Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602  | 13.6        | 27 |
| 27       | Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. <i>Chest</i> , <b>2015</b> , 148, 196-201  | 5.3         | 26 |
|          |   |             |    |
| 26       | Correlation of structure and function in idiopathic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1995</b> , 151, 1180-8   | 10.2        | 22 |
| 26<br>25 |   | 10.2<br>3.9 | 17 |
|          | Respiratory and Critical Care Medicine, 1995, 151, 1180-8  Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.   |             |    |
| 25       | Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.  Seminars in Respiratory and Critical Care Medicine, 2003, 24, 567-76  Bronchoalveolar lavage fluid neutrophils increase after corticosteroid therapy in smokers with  |             | 17 |
| 25<br>24 | Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 567-76  Bronchoalveolar lavage fluid neutrophils increase after corticosteroid therapy in smokers with idiopathic pulmonary fibrosis. The American Review of Respiratory Disease, 1986, 133, 104-9 | 3.9         | 17 |

| <b>2</b> 0 | INFILTRATIVE AND INTERSTITIAL LUNG DISEASE IN THE ELDERLY PATIENT. <i>Clinics in Chest Medicine</i> , <b>1993</b> , 14, 501-521   | 5.3               | 11 |
|------------|---|-------------------|----|
| 19         | Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. <i>Journal of Occupational and Environmental Medicine</i> , <b>2010</b> , 52, 647-52                          | 2                 | 8  |
| 18         | The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1058-62   | 4.6               | 7  |
| 17         | Lessons From an Educational Never Event. <i>JAMA Internal Medicine</i> , <b>2017</b> , 177, 1415-1416   | 11.5              | 7  |
| 16         | Bosentan for idiopathic pulmonary fibrosis. Current Opinion in Investigational Drugs, 2008, 9, 1171-9   |                   | 6  |
| 15         | Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. <i>Rheumatology International</i> , <b>2001</b> , 21, 122-6   | 3.6               | 5  |
| 14         | Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. <i>Respirology</i> , <b>2015</b> , 20, 389-94  | 3.6               | 4  |
| 13         | Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2004</b> , 115, 43-76; discussion 76-8 | 0.9               | 4  |
| 12         | Surgical lung biopsy in the diagnosis of idiopathic NSIP: do we always need it in the initial approach?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 1071; author reply 107          | 1 <sup>10.2</sup> | 3  |
| 11         | Idiopathic Interstitial Pneumonias <b>2010</b> , 1356-1397  |                   | 3  |
| 10         | Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 1272           | 10.2              | 2  |
| 9          | Diffuse Lung Disease: Classification and Evaluation <b>2012</b> , 85-100  |                   | 2  |
| 8          | Understanding Nonspecific Interstitial Pneumonia: The Need for a Diagnostic Gold Standard. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 256-256                                       | 10.2              | 1  |
| 7          | Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.  American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1292-3; author reply 1293                              | 10.2              | 1  |
| 6          | Cryptogenic Organizing Pneumonia New England Journal of Medicine, 2022, 386, 1058-1069  | 59.2              | 1  |
| 5          | Idiopathic Interstitial Pneumonias <b>2016</b> , 1118-1152.e19  |                   |    |
| 4          | Pathologic and Immunologic Alterations in Early Stages of Beryllium Disease: Re-examination of Disease Definition and Natural History. <i>The American Review of Respiratory Disease</i> , <b>1989</b> , 140, 1834-183          | 35                |    |
| 3          | On the differential diagnosis of chronic beryllium disease and sarcoidosis. <i>The American Review of Respiratory Disease</i> , <b>1990</b> , 142, 739-40   |                   |    |

#### LIST OF PUBLICATIONS

- 2 Idiopathic Interstitial Pneumonias **2006**, 188-197
- Clinical and Radiologic Diagnosis of Interstitial Infiltrates **2008**, 105-140